Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PRE-RA Clear all
Completed Phase 2 Interventional Results available

Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)

NCT02093026
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisolone, Folic Acid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
42
States / cities
Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

NCT03093428
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 23, 2026, 8:52 AM EDT
Recruiting Not applicable Interventional

Interactive Computer-adaptive Chronic Kidney Disease Education Program

NCT06364358
View directory record Official record
Conditions
Chronic Kidney Diseases, Hypertension
Interventions
Computerized CKD Education, Usual Hospital Care
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Teach-to-Goal Education vs. Brief Education for Children

NCT04373499
View directory record Official record
Conditions
Asthma, Bronchospasm, Shortness of Breath
Interventions
Virtual Teach to Goal, Brief Intervention
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
5 Years to 10 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 23, 2026, 8:52 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Baricitinib Curative Repression of HIV-1

NCT07209267
View directory record Official record
Conditions
HIV Infection, HIV
Interventions
Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 23, 2026, 8:52 AM EDT
Completed No phase listed Observational

Use of Thermal and 3D Imaging to Quantify Arthritis

NCT01044823
View directory record Official record
Conditions
Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis
Interventions
3D and thermal imaging
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
4 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 23, 2026, 8:52 AM EDT
Terminated Phase 3 Interventional Results available

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

NCT01770379
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Secukinumab (AIN457), Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
25
States / cities
Peoria, Arizona • Santa Monica, California • Upland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

NCT01351480
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
abatacept
Biological
Lead sponsor
Arthritis & Rheumatic Disease Specialties Research
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 23, 2026, 8:52 AM EDT
Not listed No phase listed Observational

Telehealth-delivered HealthcaRe to ImproVe Care

NCT05483855
View directory record Official record
Conditions
Telemedicine
Interventions
Objective 1 Only: Telehealth Satisfaction Survey, Objective 2 Only: ArthritisPower Joint Assessment
Other
Lead sponsor
Attune Health Research, Inc.
Industry
Eligibility
19 Years and older
Enrollment
1,580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 23, 2026, 8:52 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Tirzepatide Impact Assessment Study

NCT07740291
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
Interventions
GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
Drug · Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 23, 2026, 8:52 AM EDT
Active, not recruiting Not applicable Interventional

Behavioral Economic and Wellness-based Approaches for Reducing Alcohol Use and Consequences Among Emerging Adults

NCT04776278
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Brief Alcohol Intervention (BAI), Substance-free Activity Session (SFAS), Relaxation Training (RT), Education Control
Behavioral · Other
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 29 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 23, 2026, 8:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

NCT03653338
View directory record Official record
Conditions
Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
Interventions
CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

NCT03938636
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tc 99m tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobilized Psychoeducation and Skills Based Intervention (Pep-Pal) for Caregivers of Patients With Advanced Illness

NCT03002896
View directory record Official record
Conditions
Distress, Anxiety, Depression
Interventions
Pep-Pal, Treatment as Usual
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Not applicable Interventional Results available

Breast Cancer Risk Reduction: A Patient Doctor Intervention

NCT01830933
View directory record Official record
Conditions
Breast Cancer
Interventions
BreastCARE
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 74 Years
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Results available

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

NCT04163016
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Interventions
Pharmacokinetics of certolizumab pegol
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Not applicable Interventional Results available

Interventions for Parent Caregivers of Injured Military/Veteran Personnel

NCT03309046
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Brain Injuries, Traumatic
Interventions
REACH Individual Session, Education Webinar
Other
Lead sponsor
Memphis VA Medical Center
Federal
Eligibility
Not listed
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 23, 2026, 8:52 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

HIV Prevention Intervention for Latino Male Couples

NCT06131931
View directory record Official record
Conditions
HIV
Interventions
CLP Intervention, WP Intervention
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Not applicable Interventional

One Team: Changing the Culture of Youth Sport With Pregame Safety Huddles

NCT04099329
View directory record Official record
Conditions
Concussion, Brain
Interventions
Pre-game Safety Huddles
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 14 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 23, 2026, 8:52 AM EDT
Active, not recruiting Phase 2 Interventional

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365
View directory record Official record
Conditions
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 23, 2026, 8:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Duration of Immune Response to Influenza Vaccination in Patients With RA

NCT02311855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Influenza vaccine
Biological
Lead sponsor
Bassett Healthcare
Other
Eligibility
40 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 23, 2026, 8:52 AM EDT
Recruiting Early Phase 1 Interventional

GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

NCT06338553
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Semaglutide (Rybelsus®), Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 23, 2026, 8:52 AM EDT
Active, not recruiting No phase listed Observational

Anti-obesity Pharmacotherapy and Inflammation

NCT05756764
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
35 Years to 60 Years
Enrollment
30 participants
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 23, 2026, 8:52 AM EDT